tiprankstipranks
Trending News
More News >
DocCheck AG (DE:AJ91)
XETRA:AJ91
Advertisement

DocCheck AG (AJ91) AI Stock Analysis

Compare
3 Followers

Top Page

DE

DocCheck AG

(XETRA:AJ91)

Rating:80Outperform
Price Target:
€13.50
▲(8.87%Upside)
DocCheck AG's stock score is driven by strong technical indicators, reflecting positive market momentum and a healthy valuation with a high dividend yield. Financial performance is solid, though challenges include declining revenue and assets. These factors contribute to the overall positive outlook.

DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)

DocCheck AG Business Overview & Revenue Model

Company DescriptionDocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.
How the Company Makes MoneyDocCheck AG generates revenue through multiple channels. The company runs a robust online platform that connects healthcare professionals, offering subscription-based services and premium memberships which provide access to specialized content and networking opportunities. Additionally, DocCheck AG operates an e-commerce platform that sells medical supplies and equipment, earning revenue through product sales and distribution. The company also offers digital marketing and advertising services to healthcare businesses, leveraging its extensive network and industry expertise to create targeted marketing campaigns. This combination of e-commerce, subscription services, and advertising revenue forms the core of DocCheck AG's business model.

DocCheck AG Financial Statement Overview

Summary
DocCheck AG displays a solid financial performance with strong profitability and efficient cash flow management. It maintains a prudent balance sheet with low leverage, although declining revenue and assets pose potential challenges.
Income Statement
75
Positive
DocCheck AG's income statement shows strong profitability with a gross profit margin of 19.6% and a net profit margin of 9.8% for the latest annual period. Revenue growth has been relatively stable, with a modest increase of 0.7% from the previous year. The EBIT margin improved substantially to 12.0% from 6.6%, indicating enhanced operational efficiency. However, there is a concern over the company's declining total revenue over the last few years, which may impact future profitability.
Balance Sheet
70
Positive
The balance sheet of DocCheck AG reflects a solid financial position with a low debt-to-equity ratio of 0.12, suggesting conservative leverage. The equity ratio stands at 65.9%, indicating a strong equity base relative to total assets. Return on equity is healthy at 13.2%, showcasing efficient use of equity capital. However, declining total assets and stockholders' equity in recent periods may pose potential risks to long-term financial stability.
Cash Flow
80
Positive
The cash flow statement highlights a robust operating cash flow to net income ratio of 1.48, demonstrating strong cash generation relative to net income. Free cash flow increased by 21.3% year-over-year, reflecting effective cash management. The company maintains a positive free cash flow to net income ratio of 1.29, underscoring its ability to generate surplus cash after capital expenditures. Nevertheless, fluctuations in free cash flow over recent years warrant monitoring.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue53.79M53.41M60.90M85.92M63.10M
Gross Profit10.53M12.97M14.08M21.54M18.26M
EBITDA10.18M9.38M13.38M20.09M15.90M
Net Income5.28M2.27M6.29M11.40M9.20M
Balance Sheet
Total Assets60.86M56.14M63.28M60.25M46.99M
Cash, Cash Equivalents and Short-Term Investments21.02M17.52M15.66M21.52M19.99M
Total Debt5.01M5.85M7.07M7.03M1.61M
Total Liabilities20.78M18.11M23.86M22.08M15.64M
Stockholders Equity40.08M37.33M38.57M37.31M30.91M
Cash Flow
Free Cash Flow6.82M5.62M-557.91K6.90M9.15M
Operating Cash Flow7.82M7.51M5.89M10.92M12.57M
Investing Cash Flow-1.65M-2.02M-4.92M-4.39M-936.57K
Financing Cash Flow-3.50M-4.54M-5.81M-5.86M-1.08M

DocCheck AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.40
Price Trends
50DMA
11.86
Positive
100DMA
10.64
Positive
200DMA
9.47
Positive
Market Momentum
MACD
0.16
Positive
RSI
60.62
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Positive. The current price of 12.4 is above the 20-day moving average (MA) of 12.11, above the 50-day MA of 11.86, and above the 200-day MA of 9.47, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 60.62 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:AJ91.

DocCheck AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
80
Outperform
€61.92M11.8113.65%5.80%0.69%132.12%
52
Neutral
$7.46B-0.04-63.82%2.49%16.43%<0.01%
€1.27B46.174.03%4.15%
€45.14M10.8324.14%3.46%
€1.23B38.0211.87%0.33%
€88.90M27.55-64.04%
€54.71M
0.38%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:AJ91
DocCheck AG
12.40
4.99
67.34%
GB:0MSD
CompuGroup Medical
24.12
8.45
53.92%
GB:0HI7
MeVis Medical Solutions
25.60
0.00
0.00%
GB:0FGL
NEXUS AG
70.70
14.64
26.11%
GB:0NLV
VITA 34
4.88
0.40
8.93%
DE:HAEK
HAEMATO AG
10.50
-5.44
-34.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025